DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis

Highlights
- Identification of DNA-PKcs-modulated transcriptional networks and consequence
- DNA-PKcs-mediated gene regulation promotes migration, invasion, and metastases
- DNA-PKcs is upregulated and highly activated in aggressive human tumors
- DNA-PKcs independently predicts for metastases, recurrence, and poor survival

Authors
Jonathan F. Goodwin, Vishal Kothari, Justin M. Drake, ..., Owen N. Witte, Felix Y. Feng, Karen E. Knudsen

Correspondence
karen.knudsen@jefferson.edu

In Brief
Goodwin et al. identify DNA-PKcs as a promising therapeutic target that drives prostate cancer progression and metastasis through transcriptional regulation. DNA-PKcs is significantly elevated in advanced disease and is an independent predictor of metastasis, recurrence, and poor survival.

Accession Numbers
GSE63480
SUMMARY

Emerging evidence demonstrates that the DNA repair kinase DNA-PKcs exerts divergent roles in transcriptional regulation of unsolved consequence. Here, in vitro and in vivo interrogation demonstrate that DNA-PKcs functions as a selective modulator of transcriptional networks that induce cell migration, invasion,
INTRODUCTION

The DNA-dependent protein kinase (DNA-PK) is a serine/threonine protein kinase complex composed of a Ku heterodimer (Ku70/Ku80) and a catalytic subunit (DNA-PKcs) that plays an important role in the DNA damage response (DDR) and maintenance of genomic stability. In this context, DNA-PK primarily mediates ligation of DNA double-strand breaks (DSBs) through nonhomologous end joining (NHEJ), wherein the Ku heterodimer recognizes and binds broken DNA ends, facilitating recruitment and activation of DNA-PKcs (Yoo and Dynan, 1999). Activated DNA-PKcs phosphorylates and alters the function of factors that mediate NHEJ, including DNA-PKcs itself and histone H2AX (γH2AX) (An et al., 2010; Chan et al., 2002). While mechanisms governing DNA-PKcs activity are incompletely defined, it is clear that DNA-PKcs activation is critical for DNA DSB repair (Kurimasa et al., 1999; Zhao et al., 2006).

DNA-PKcs expression has been shown to correlate with decreased therapeutic response to DNA-damaging agents in multiple cancers, implicating DNA-PKcs-mediated DNA repair as a mechanism for tumor cell survival (Beskow et al., 2009; Bouchaert et al., 2012). However, DNA-PKcs has also been linked to poor prognosis in the absence of DNA-damaging therapies (Evert et al., 2013; Willmore et al., 2008), suggesting a DDR-independent role for DNA-PKcs in human malignancies. Studies further identified DNA-PKcs as a modulator of cancer-associated pathways distinct from DNA repair, including hypoxia, metabolism, inflammatory response, and transcriptional regulation (Goodwin and Knudsen, 2014). Notably, DNA-PKcs was originally discovered and characterized as part of SP1 transcriptional complexes (Jackson et al., 1990) and as a regulatory component of transcriptionally poised RNA polymerase II (RNAPII) (Ovri et al., 1992); accordingly, recent studies revealed that DNA-PKcs is recruited to active sites of transcription (Ju et al., 2006). DNA-PKcs can interact with the basal transcriptional machinery (Maldonado et al., 1996) and both binds and modulates the function of multiple sequence-specific transcription factors (e.g., AIRE, p53, and ERG) as well as select nuclear receptors (including the glucocorticoid, progesterone, estrogen [ER], and androgen receptors [AR]) (Goodwin and Knudsen, 2014). Recently, a critical link was identified between AR signaling and DNA-PKcs that underlies the capacity of this steroid hormone receptor to promote DSB repair (Goodwin et al., 2013; Polkinghorn et al., 2013). Briefly, it was shown that AR binds to the regulatory locus of PRKDC (the gene encoding DNA-PKcs) in response to androgen stimulation and DNA damage, thereby inducing PRKDC expression and subsequent DNA-PKcs activity. This induction proved essential for AR-mediated DSB repair and cell survival in the presence of genomically intact, and elevated levels of DNA-PKcs were shown to create a positive feedback loop by virtue of the established ability of DNA-PKcs to serve as an AR comodulator. These findings provided the mechanistic basis for clinical observations demonstrating that suppression of AR activity enhances the response to radiotherapy (Al-Ubaidi et al., 2013; Warde et al., 2011), concordant with reports showing that AR suppression dampens expression of repair factors in prostatic adenocarcinoma (PCa) (Al-Ubaidi et al., 2013; Warde et al., 2011), and illustrated the significance of AR-DNA-PKcs interplay in PCa. Given the potential implications of DNA-PKcs-mediated transcriptional activity in human malignancies, it was imperative to discern the molecular basis of DNA-PKcs function and the contribution of DNA-PKcs-mediated transcriptional regulation on tumor phenotypes.

RESULTS

DNA-PKcs Interacts with AR and Is Recruited to Sites of AR Action

Because DNA-PKcs is induced by AR activity and functions as an AR coactivator in advanced PCa that can bypass antiandrogen therapy (castration-resistant PCa, CRPC), CRPC models were selected to interrogate DNA-PKcs-mediated transcriptional regulation. PCa depends on AR activity for growth and progression, and therapies that suppress AR activity through ligand deprivation are the first line of intervention for metastatic disease. Although effective, tumors ultimately recur, almost invariably through restoration of AR activity (Knudsen and Scher, 2009). Thus, discerning the impact of DNA-PKcs on AR function in CRPC is of translational relevance. Consistent with identification of PRKDC and XRCC6 as androgen-regulated genes in CRPC (Al-Ubaidi et al., 2013; Goodwin et al., 2013), hormone deprivation decreased DNA-PKcs S2056 phosphorylation (indicative of decreased activity; Chen et al., 2005) along with total DNA-PKcs and Ku70 levels (Figure 1A). As such, studies assaying the function of DNA-PKcs as a transcriptional regulator were performed in hormone-proficient conditions. Loci explored initially focused on gene regulatory elements governed by AR and ERG in PCa cells, as DNA-PKcs was implicated as a modulator of both factors. As predicted, chromatin immunoprecipitation (ChIP) analysis revealed AR occupancy at two well-characterized loci (KLK3/PSA and TMPRSS2 enhancers), but not at the promoter of the ERG-regulated gene PLA1A (Figure 1B, left). DNA-PKcs was detected at all three regions (Figure 1B, right), but not in the control region, showing specificity of DNA-PKcs binding (Brenner et al., 2011). In response to DHT, AR was recruited to each AR regulatory site within 30 min, with maximum occupancy at 16 hr post-treatment (Figure 1C, top left; Figure S1A). In contrast, DNA-PKcs recruitment was delayed (6 hr post-treatment) at AR regulatory regions with maximum occupancy at 16 hr (Figure 1C, top right; Figure S1A), and unchanged at PLA1A, demonstrating specificity of the DNA-PKcs response to hormone stimulation (Figure 1C, top). The AR

and metastasis. Accordingly, suppression of DNA-PKcs inhibits tumor metastases. Clinical assessment revealed that DNA-PKcs is significantly elevated in advanced disease and independently predicts for metastases, recurrence, and reduced overall survival. Further investigation demonstrated that DNA-PKcs in advanced tumors is highly activated, independent of DNA damage indicators. Combined, these findings reveal unexpected DNA-PKcs functions, identify DNA-PKcs as a potent driver of tumor progression and metastases, and nominate DNA-PKcs as a therapeutic target for advanced malignancies.
coregulator p300 was enriched 30 min post-DHT, followed by RNAPII binding (3–6 hr) at the AR regulatory loci, while neither was enriched at the PLAT1A promoter in response to DHT (Figure 1C, bottom; Figure S1A), suggesting that DNA-PKcs binding facilitates coactivator function and potentiates transcriptional activation. DNA-PKcs levels were not significantly enriched after DHT treatment at these early time points (Figure S1B). Notably, DNA-PKcs detection was abrogated at all three loci by siRNA-mediated depletion (Figure S1C), but was specifically undetected at AR-regulated loci after treatment with the AR antagonist MDV3100 (Figure S1D). Combined, these findings suggest that DNA-PKcs is recruited to sites of AR function in response to AR and initiating p300 occupancy, facilitating active transcription. The impact of DNA-PKcs recruitment was determined in parallel. PLAT1A was not induced in response to DHT, and while significant induction of both KLK3/PSA and TMPRSS2 was observed 3 hr post-DHT (Figure 1D), maximum induction was not observed until after peak recruitment of AR and DNA-PKcs. Further analyses revealed that AR and DNA-PKcs are found in complex, and that the interaction is not further enriched by exogenous DHT (Figure 1E). The AR-DNA-PKcs interaction is not dependent on DNA binding, because pre-addition of 2011)(Figure S1 E). Further, co-immunoprecipitation in 22Rv1 cells (which contain full-length AR and an AR splice variant, AR-V7, lacking the ligand binding domain (LBD); Guo et al., 2009) revealed DNA-PKcs interaction with AR-V7 (Figure S1F), suggesting that DNA-PKcs can bind AR-V7-containing complexes, in contrast, in vitro interaction between Ku70 and AR was mapped to the AR LBD (Mayeur et al., 2005). Finally, DNA-PKcs activity was not required for AR interaction but is important for AR function, as a highly selective DNA-PKcs inhibitor, NU7441 (Zhao et al., 2006)(Figures S1G and S1H) did not suppress complex formation but decreased DHT-stimulated AR activity (Figure S1I). In sum, these findings reveal that DNA-PKcs is found in complex with AR and facilitates AR-dependent transcriptional transactivation. DNA-PKcs Is a Selective Effector of Transcriptional Networks Given the impact of DNA-PKcs on AR, subsequent studies were directed at identifying the totality of DNA-PKcs mediated transcriptional networks. Initial gene expression analyses were performed in CRPC cells either depleted of DNA-PKcs or treated with NU7441 (Figure 2A, left); as shown, the siPKDC pool suppressed DNA-PKcs expression, whereas NU7441 had no effect on DNA-PKcs levels, and neither affected Ku70 expression (Figure 2A, right). Genes up- or downregulated by >1.5-fold were selected for further analysis (Figure 2B). For both manipulations, the number of genes downregulated far exceeded those that were upregulated, suggesting that DNA-PKcs primarily positively regulates transcriptional events. Comparison between groups demonstrated that DNA-PKcs depletion results in overlapping but distinct effects as compared to enzymatic inhibition. To minimize potential off-target effects of NU7441, subsequent analyses primarily focused on transcriptional alterations induced by DNA-PKcs knockdown. Gene Set Enrichment Analysis (GSEA) and associated motif analysis revealed significant enrichment of genes regulated by MAZ, MYC, and the known DNA-PKcs-interacting partner SP1, validating the concept that DNA-PKcs modulates a select subset of transcriptional networks (Figure 2C). Gene ontology (GO) analysis demonstrated that genes sensitive to DNA-PKcs associate with distinct biological processes, including transcription and regulation of gene expression, further supporting a role for DNA-PKcs in gene regulation (Figure 2D). Combined, these findings begin to define the cellular consequence of DNA-PKcs-mediated transcriptional regulation and demonstrate that DNA-PKcs selectively governs transcriptional networks. DNA-PKcs and AR Cooperate to Suppress UGT Enzyme Expression in CRPC Numerous metabolic and hormone pathways of potential clinical impact in PCa were upregulated by DNA-PKcs depletion (Figure 3A), including steroid hormone biosynthesis, which exhibited upregulation of UGT glycosyltransferases (Figure 3B). UGT enzymes catalyze transfer of glucuronic acid to small molecules (including androgens), facilitating metabolism and excretion (Rowland et al., 2013). In the prostate, local androgen inactivation occurs when DHT is directly modified by glucuronidation or is metabolized to 5α-androstane-3α-diol (3α-diol) and androsterone (AST), which are then glucuronidated by UGT2B15 and UGT2B17. Consistent with previous reports suggesting that these genes are also AR regulated (Bao et al., 2008), AR occupied the proximal promoters of both UGT2B15 and 2B17, with a modest but significant increase observed upon DNA-PKcs depletion (Figures 3C and 3D, left). DNA-PKcs co-occupied these sites (Figure 3D, right), suggesting that negative regulation by DNA-PKcs is direct. DNA-PKcs depletion resulted in increased UGT2B15 and 2B17 expression, underscoring the impact of DNA-PKcs on this pathway (Figure 3E). Previous studies showed that DNA-PKcs negative transcriptional regulation can be mediated through NCoR and SMRT (Jeyakumar et al., 2007; Yu et al., 2006), and both were both enriched at the UGT2B15 and 2B17 promoters. Corepressor binding was significantly reduced by DNA-PKcs depletion (Figure S2A), but not after kinase inhibition (Figure S2B), suggesting that DNA-PKcs occupancy (but not activity) is needed for NCoR and SMRT residence. As expected, DHT stimulation decreased UGT2B15 and 2B17, which was partially reversed by DNA-PKcs depletion (Figure S2C), consistent with a role for DNA-PKcs in negative regulation. Because UGT2B15 and 2B17 protein accumulation was also enhanced after DNA-PKcs depletion (Figure 3F), the impact of DNA-PKcs depletion on DHT metabolites was quantified by high-pressure liquid chromatography (HPLC) (Figure S2D). Cells depleted of DNA-PKcs trended toward decreased overall levels of free DHT, but did not reach statistical significance (Figure 3G, left) and there was no impact on G-DHT (Figure 3G, right) or G-AST (Figure S2E), suggesting that elevated UGT2B15 and 2B17 is not sufficient to independently alter hormone metabolism. Similar regulation of other UGT enzymes after DNA-PKcs depletion (Figure 3B) argues against functional redundancy affecting DHT levels. The overall findings are of translational significance, because UGT2B15 and 2B17 are being developed as prognostic markers and therapeutic targets in PCa (Grosse et al., 2013), and the mechanisms of regulation are not well understood. To assess clinical
Figure 1. DNA-PKcs Binds AR and Is Recruited to Sites of AR Action
(A) C4-2 cells were treated with ADT (CSS) for 24 hr and immunoblot analysis for phospho-S2056 DNA-PKcs, total DNA-PKcs, and Ku70 was performed.
(B and C) C4-2 cells in hormone-proficient media were (B) harvested for ChIP-qPCR analysis and percent (input) occupancy of AR (left) or DNA-PKcs (right) reported or (C) treated with 10 nM DHT and harvested for ChIP-qPCR analysis with percent (input) occupancy of AR, DNA-PKcs, p300, or RNAPII set relative to control at each time point.

(legend continued on next page)
relevance, a cohort of 232 patients with high-risk localized PCA was examined, wherein it was observed that both UGT2B15 (correlation coefficient $\rho = 0.28$, $p < 0.0001$) and UGT2B17 (correlation coefficient $\rho = 0.38$, $p < 0.0001$) expression strongly negatively correlated with DNA-PKcs (Figure 3H), supporting the concept that DNA-PKcs suppresses expression of UGT enzymes in human tumors. Further analysis in response to NU7441 confirmed the function of DNA-PKcs as a selective negative regulator of transcription (Figure S2F). On balance, these findings identify gene networks that are negatively regulated by DNA-PKcs and identify DNA-PKcs as a key modulator of the UGT enzyme cancer-associated pathway.

**DNA-PKcs Promotes Pro-metastatic Signaling**

Whereas DNA-PKcs negatively regulates steroid regulated pathways, the majority of DNA-PKcs-mediated transcriptional

(D) C4-2 cells were treated with 10 nM DHT and relative transcript expression analyzed as normalized to GAPDH mRNA at each time point. (E and F) C4-2 cells were treated with 10 nM DHT for 6 hr and co-immunoprecipitation performed in the absence (E) or presence (F) of 50 $\mu$g/ml ethidium bromide.

Data are reported as mean ± SD. *$p < 0.05$ **$p < 0.01$. See also Figure S1.
Figure 3. DNA-PKcs and AR Cooperate to Suppress UGT Enzyme Expression in CRPC

(A) GSEA KEGG pathway analysis of genes upregulated by ≥ 1.5-fold compared to control after DNA-PKcs knockdown.

(B) Heatmap of transcript change of UGT enzymes in the DNA-PKcs knockdown groups.

(C and D) C4-2 cells depleted of DNA-PKcs were harvested for ChIP-qPCR analysis and percent (input) occupancy of AR (D, left) or DNA-PKcs (D, right) at indicated loci reported. TSS, transcriptional start site.

(E and F) CRPC cells depleted of DNA-PKcs were subject to either qPCR (E, C4-2 left, 22Rv1 right) or immunoblot (F, C4-2) analysis.

(G) Free (left) and G-DHT (right) levels in C4-2 cells depleted of DNA-PKcs were determined by HPLC.

(H) Tumor samples were profiled for mRNA expression of DNA-PKcs, UGT2B15, and UGT2B17 and correlation coefficients determined. Data are reported as mean ± SD. *p < 0.05 **p < 0.01. See also Figure S2.
effects support coactivator functions. KLK3/PSA, TMPRSS2, and other well-characterized PCA-relevant AR-regulated genes (Goodwin et al., 2013; Mayeur et al., 2005) were generally reduced after DNA-PKcs depletion (Figure S3A), as expected. Analysis of genes downregulated after DNA-PKcs depletion (Figure 4A) or NU7441 (Figure S3B) revealed enrichment in pathways associated with cancer progression (Figure 4B; Figure S3C), prominently associated with cell migration and invasion. The focal adhesion gene signature was markedly suppressed by DNA-PKcs depletion (Figure 4C) or NU7441 (Figure S3D). Factors in the focal adhesion signature have previously been implicated in PCA progression and metastasis, including PREX1 (GEF for Rac1) (Qin et al., 2009), ROCK2 (effector of Rho signaling) (Kroiss et al., 2014), Integrin β4 (ITGB4, which regulates matrix organization through the Rac1 pathway) (Yoshikawa et al., 2013), and VAV3 (GEF for Rho and Rac1) (Lyons and Bumstein, 2006). Expression of each was significantly reduced in hormone-therapy (HT)-sensitive cells (LNCaP), CRPC cells with limited metastatic potential (C4-2), and AR-negative CRPC cells with high metastatic potential (PC3-ML) after DNA-PKcs depletion (Figure 4D) or 24 hr inhibitor treatment (Figure S3E), with the exception of ITGB4 in PC3-ML cells, which was not significantly altered, suggesting a possible role for AR in regulation. As expected, ATM (ataxia telangiectasia mutated) levels were diminished after DNA-PKcs depletion but not after DNA-PKcs inhibition (Goodwin et al., 2013; Peng et al., 2005) (Figure 4E). ATM depletion did not significantly alter expression of the identified genes (Figure 4F), suggesting that these transcriptional events are not ATM mediated. Observations were confirmed using alternative strategies to deplete DNA-PKcs or a second highly selective DNA-PKcs inhibitor NU7026 (the lead compound in generation of NU7441) (Vogler et al., 2003) (Figure S3F). Kinetic analysis revealed a time-dependent decrease in target gene expression 6 hr after treatment (Figure S3G), suggesting direct impact of DNA-PKcs on transcriptional regulation. Consistently, DNA-PKcs binds to the proximal promoter regions containing motifs of known DNA-PKcs associated transcription factors for PREX1 (Wong et al., 2011), ROCK2, and ITGB4 (Drake et al., 2010) (Figure 4G). Treatment with MDV3100 modestly decreased expression of ROCK2 and ITGB4 (Figure S3H), suggesting that AR is not universally required for DNA-PKcs-mediated regulation of genes in this pathway. DNA-PKcs occupancy was further examined at the proximal promoter regions of PREX1, ROCK2, and ITGB4 after MDV3100 treatment or depletion of SP1 or MAZ, the top motifs identified. MDV3100 decreased DNA-PKcs occupancy at the ROCK2 and ITGB4 promoters but not at the PREX1 promoter, consistent with the transcript data (Figure S3I, left). SP1 depletion resulted in remarkable reduction in DNA-PKcs occupancy at the PREX1 promoter (consistent with PREX1 being regulated by SP1; Wong et al., 2011) and modest but significant reduction in occupancy at both the ROCK2 and ITGB4 promoters (Figure S3I, middle), whereas MAZ depletion produced a significant reduction in DNA-PKcs occupancy at the ITGB4 promoter, modest reduction in occupancy at the PREX1 promoter (not statistically significant), and no change at the ROCK2 promoter (Figure S3I, right). These studies reveal that DNA-PKcs-mediated expression is differentially regulated by transcription factors whose activities are modulated by DNA-PKcs. Decreased transcript expression resulted in reduced protein levels for the factors analyzed (Figure 4H), identifying DNA-PKcs as a positive regulator of metastatic signaling. PREX1, ROCK2, ITGB4, and VAV3 all interact with Rho GTPases that influence cell motility and invasion (Cook et al., 2014). DNA-PKcs depletion or inhibition decreased Rho and Rac1 activity (Figure 4I; Figure S3J). Depletion of VAV3 strongly reduced activated Rho and moderately suppressed Rac1 activity, whereas depletion of PREX1 diminished activated Rac1 with minimal effects on Rho (Figure S3K), demonstrating importance in DNA-PKcs mediated regulation of Rac/Rho signaling pathways, although other GEFs may be involved. Combined, these findings identify DNA-PKcs as a direct and positive regulator of Rac/Rho function and pro-metastatic pathways.

DNA-PKcs Promotes Metastatic Phenotypes

Given the impact of DNA-PKcs on pro-metastatic signaling, the consequence for metastatic potential was determined. Depletion of DNA-PKcs resulted in decreased migration in all models (Figure 5A, left) and invasion in the CRPC models (Figure 5A, right). Consistently, DNA-PKcs inhibition suppressed migration (Figure 5B, top) and invasion (Figure 5B, bottom) in all models. Both C4-2 and PC3-ML are CRPC lines capable of proliferating in the absence of hormone, and proliferation of LNCaP cells in hormone-deficient media was not significantly altered after DNA-PKcs inhibitor treatment (Figure S4A). The ROCK2 inhibitor reduced migration and invasion similar to that observed with NU7441 (Figure 5B). Combination of the DNA-PKcs and ROCK2 inhibitors resulted in modest but significant decreases in migration in C4-2 and PC3-ML cells and further suppressed invasion in all models compared to either inhibitor alone, suggesting that DNA-PKcs regulates migration and invasion through pathways in addition to Rac signaling. Furthermore, cells depleted of UGT2B15 or 2B17 failed to demonstrate significant changes in migratory or invasive potential (Figure S4B), suggesting that DNA-PKcs effects on metastatic phenotypes are independent from effects on metabolism. In sum, these findings establish DNA-PKcs as a positive regulator of gene expression events that induce migration and invasion.

DNA-PKcs Inhibition Delays Formation of Metastases In Vivo

To determine the impact of DNA-PKcs on metastatic development in vivo, PC3-ML cells expressing luciferase were pre-treated for 48 hr with NU7441 or vehicle and injected into the tail veins of severe combined immunodeficiency (SCID) mice. Mice were treated every 24 hr (5 days/week) with 25 mg/kg NU7441 or vehicle, and tumor formation monitored by live imaging (Figure S5A). Parallel studies wherein cells were maintained in culture revealed no significant differences in cell number or viability between the cohorts (Figure S5A). Whereas robust metastases were observed in the control arm, total tumor burden observed in the DNA-PKcs inhibitor-treated cohort was significantly reduced, demonstrating that DNA-PKcs inhibition delays formation of productive metastases in vivo (Figure 6A). These findings provide evidence linking DNA-PKcs enzymatic activity to development of metastases.

To further investigate the impact of DNA-PKcs, crossover studies were performed wherein animals in the control arm with the greatest tumor burden (denoted 1, 2, and 3) were
Figure 4. DNA-PKcs Promotes Pro-metastatic Signaling

(A) GSEA KEGG pathway analysis of genes downregulated by ≥1.5-fold compared to control after DNA-PKcs knockdown.

(B and C) Heatmap of transcript change of pathways in cancer (B) or focal adhesion (C) pathway genes in the DNA-PKcs knockdown groups.

(D) C4-2 and PC3-ML cells in hormone-proficient or LNCaP cells in hormone-deficient media treated with siDNA-PKcs or siControl were subject to qPCR analysis with control dataset to one for each cell line.

(E) Immunoblot analyses of C4-2 cells depleted of DNA-PKcs or treated with 1 μM NU7441.

(F) C4-2 cells depleted of ATM were harvested for qPCR analysis with relative expression of indicated transcripts analyzed and normalized to GAPDH.

(legend continued on next page)
switched to the NU7441 arm; conversely, 3 mice randomly selected from the NU7441 arm (denoted 4, 5, and 6) were removed from treatment. After 2 weeks, animals moved from control to NU7441 failed to show reductions in tumor burden at established sites of metastases, consistent with the concept that DNA-PKcs inhibitors block development of productive metastases rather than suppressing tumor growth (Figure 6B). Conversely, animals released from NU7441 incurred dramatic induction of metastatic burden, with the tumor-doubling time reduced by ~50%–90% (Figure 6C), suggesting that resurgent DNA-PKcs activity drives metastatic development. Mice not selected for crossover were continued on study, and total tumor burden remained suppressed in the NU7441 cohort but not the control arm (Figure S5B). Proliferation rates of the metastatic lesions in the lungs were similar in both crossover cohorts (Figure S5C), again suggesting that tumor changes in animals released from inhibitor illustrate the impact of DNA-PKcs on metastases and not proliferation, although it is possible that NU7441 treatment of large tumors in the crossover may be less effective due to tumor size. Experiments using AR-positive 22Rv1 cells also demonstrated a significant decrease in overall metastatic tumor burden (Figure S5D), although this model is less aggressive in developing metastatic lesions. Combined, these findings clearly reveal that DNA-PKcs induces tumor metastases in vivo, confirming the importance of DNA-PKcs regulated pathways in metastatic development.

To further characterize the impact of DNA-PKcs on metastatic development in AR-positive but aggressive models of spontaneous metastasis, CASP-NPK-YPF tumor cells (Aytes et al., 2013) were engrafted into nude mice. Post-engraftment (5 days), mice were randomized for treatment with 25 mg/kg NU7441 or vehicle (5 days/week for 30 days) (Figure S5E). DNA-PKcs suppression decreased overall tumor burden (Figure 6D), although primary tumor weight was not significantly altered between the treatment groups (Figure S5F); in contrast, significant reduction of metastatic lung lesions was observed in the inhibitor treated cohort, with a less pronounced but similar trend in liver metastases (Figure 6E). Finally, analysis of tumors harvested at sacrifice revealed significant decrease in transcript expression of Prex1, Rock2, Itgb4, and Vav3 (Figure 6F), demonstrating that DNA-PKcs modulates expression of these four metastatic genes and promotes development of metastatic lesions in vivo. Thus, DNA-PK promotes metastatic signaling and tumor metastases in both AR-positive and AR-negative cancers.

DNA-PKcs Inhibition Modulates Expression of Pro-metastatic Factors in Primary Human Tumors

Transcriptional regulatory functions of DNA-PKcs on pro-metastatic factors were further assessed using an ex vivo culture system of primary human PCAs, in which tissue obtained immediately upon surgical resection can be subdivided, cultured, and subjected to targeted therapy as previously described (Centenera et al., 2013) (Figure 7A). Explant specimens retain the complex 3D structure and microenvironment of the original tumor and can be used for clinical assessment of targeted agents (Centenera et al., 2013; Schiewer et al., 2012). Although major alterations in histology were not observed after exposure to NU7441 (Figure 7B), DNA-PKcs inhibition effectively suppressed expression of PREX1, ROCK2, ITGB4, and VAV3 (Figure 7C). In sum, these findings confirm that DNA-PKcs inhibition regulates expression of pro-metastatic factors in primary human tumors.

DNA-PKcs Expression and Activity Predicts Clinical Disease Recurrence and Metastatic Development

Finally, the prognostic impact of DNA-PKcs in the clinical setting was investigated. A cohort of 232 patients with high-risk localized PCa was examined to assess the relevance of DNA-PKcs expression on outcomes following prostatectomy. As shown, elevated DNA-PKcs conferred reduced freedom from biochemical recurrence (Figure 8A, p = 0.050, hazard ratio [HR] = 1.5), and dramatically worse freedom from metastatic progression (Figure 8B, p = 0.0004, HR = 2.4), PCA-specific survival (Figure S6A, p = 0.001, HR = 2.8), and overall survival (Figure 8C, p < 0.0002, HR = 3.1). These results were comparable to the HRs of high Gleason score for these same outcomes (biochemical recurrence: HR = 1.3, p = 0.1; metastasis: HR = 2.2, p = 0.0007; PCA-specific survival: HR = 4.4, p < 0.0001; overall survival: HR = 2.2, p = 0.003). Because Gleason score is one of the strongest known predictors for aggressive disease (Van der Kwast, 2014), these data illustrate the potent role of DNA-PKcs in promoting lethal PCa. Further, analysis of DNA-PKcs correlated genes showed significant enrichment in the AR pathway (Figure 8D, p < 0.0001, normalized enrichment score [NES] = 2.673), the AR transcription factor pathway (Figure S6B, p < 0.0001, NES = 2.474), MAZ targets (Figure 8E, p < 0.0001, NES = 1.689), SP1 targets (Figure 8F, p < 0.0001, NES = 1.758), and the focal adhesion pathway (Figure 8G, p < 0.0001, NES = 1.635), thus validating the preclinical findings. As expected, multiple pathways associated with DDR were also enriched (Table S1). DNA-PKcs was significantly positively correlated with AR, SP1, and MAZ expression in the clinical samples (Figure S6C, correlation coefficients of 0.68, 0.77, and 0.70, respectively, all p < 0.0001), further supporting the functional connectivity. Finally, elevated UGT2B15, but not 2B17, was associated with decreased freedom from metastases (Figure S6D). These findings, compared with previous reports (Mitsiades et al., 2012; Pâquet et al., 2012), provide the basis for future studies directed at discerning the potentially divergent roles of UGT2B15 and 2B17 in CRPC progression. These observations identify DNA-PKcs as markedly upregulated in advanced disease, confirm the link between DNA-PKcs and metastatic signaling, and strongly support the contention that DNA-PKcs mediated transcriptional regulation is a major effector of lethal tumor phenotypes.

To further interrogate the link between DNA-PKcs and metastasis, an independent cohort was analyzed wherein DNA-PKcs

---

(G) C4-2 cells harvested for ChIP-qPCR analysis and percent (input) occupancy of DNA-PKcs at the indicated regulatory regions.
(H) C4-2 cells depleted of DNA-PKcs or treated with 1 μM NU7441 for 48 hr were subject to immunoblot analysis.
(I) C4-2 cells depleted of DNA-PKcs or treated with 1 μM NU7441 for 48 hr were analyzed for activated (GTP-bound) Rho and Rac1 by column binding followed by immunoblot.

Data are reported as mean ± SD. *P < 0.05, **P < 0.01. See also Figure S3.
phosphorylation was quantified by phospho-proteomic analyses of fresh clinical specimens from organ confined, treatment naive PCa versus metastatic CRPC. Multiple DNA-PKcs residues were hyper-phosphorylated in metastatic CRPC, including Thr2609, an autophosphorylation residue also reported to be phosphorylated by ATM (Chen et al., 2007) and indicative of enzymatic hyper-phosphorylation.
activation (Chan et al., 2002) (Figure 8H; Table S2). These findings reveal that DNA-PKcs is not only present, but also highly active in late stage, metastatic CRPC. In contrast, analysis of γH2AX, a marker of DNA DSBs, in metastatic tissues demonstrated no detectable change in phosphorylation levels compared to treatment-naive tissues (Figure 8H), suggesting that the heightened DNA-PKcs activation is not the result (or readout) of elevated DNA damage in metastatic tissues. Combined, these clinical analyses reveal that DNA-PKcs expression predicts for disease recurrence and DNA-PKcs phosphorylation suggests significant activation in metastatic tissues independent of heightened damage response, validating the preclinical evidence that DNA-PKcs is a master regulator of transcriptional events driving disease progression and development of metastatic lesions (Figure 8).

DISCUSSION

Understanding mechanisms contributing to tumor progression and metastatic development is crucial for development of effective therapeutic strategies targeting advanced cancers. This study identifies DNA-PKcs as a key contributor to metastatic progression, mediated through transcriptional regulation. Key findings reveal that (1) DNA-PKcs interacts with AR and is recruited to regulatory loci of AR target genes upon DHT stimulation, facilitating transcriptional activation; (2) DNA-PKcs selectively modifies transcriptional networks associated with tumor progression, and is recruited to loci regulated by DNA-PKcs-associated transcription factors; (3) UGT enzymes are negatively regulated by DNA-PKcs, implicating DNA-PKcs in pathways associated with therapeutic relapse; (4) DNA-PKcs positively regulates a transcriptional network that promotes pro-metastatic signaling, resulting in DNA-PKcs-induced tumor cell migration and invasion; (5) pharmacological DNA-PKcs inhibition prevents formation of metastases in vivo; (6) analyses of clinical specimens reveal that DNA-PKcs is elevated and highly active in advanced disease, distinct from marks of DNA damage; and (7) DNA-PKcs dysregulation is strongly associated with development of distant metastases and reduced survival. In sum, these findings strongly support a model wherein the transcriptional regulatory functions of DNA-PKcs induce a pro-metastatic signaling program that drives tumor metastases and lethal disease. These studies not only define DNA-PKcs as a metastatic driver and a putative biomarker of disease progression, but also nominate DNA-PKcs as a therapeutic target.

Data here are consistent with literature identifying DNA-PKcs as associated with sequence-specific transcription factors. Recent studies identified DNA-PKcs in ER/coregulator complexes (Foulds et al., 2013) and as an AR coactivator (Goodwin et al., 2013; Mayeur et al., 2005). This study provides direct insight into the mechanism of coordinated transcriptional regulation between AR and DNA-PKcs, wherein DNA-PKcs is recruited with delayed kinetics to sites of AR function, and is required for maximum AR activity. Among the AR target genes sensitive to DNA-PKcs regulation, TMPRSS2 was recently shown to promote metastasis (Lucas et al., 2014), providing another mechanism by which DNA-PKcs may modulate metastatic development. Ongoing investigation is directed at discerning the impact of DNA-PKcs on the chromatin microenvironment surrounding AR and DNA-PKcs binding. The studies herein identify DNA-PKcs as an AR coregulator, supporting a role for DNA-PKcs in cancer-relevant transcriptional events.

Consistent with these findings, emerging evidence links DNA repair factors to transcriptional regulation. Initial studies reported that recruitment of DDR machinery was primarily the result of transient, site-specific DSBs required for transcriptional activation (Ju et al., 2006). Furthermore, the gene rearrangements observed in PCAs can result from fusion events in transcriptional hubs bringing together distant chromosomal regions (Tomlins et al., 2005), suggesting that DNA repair capacity is needed at sites of active transcription. However, recent findings suggest that repair factors hold transcriptional regulatory functions independent of damage response, as exemplified by PARP1, a DNA repair factor with roles in transcriptional regulation whose functions can be segregated (Steffen et al., 2014). Whereas the effects of DNA-PKcs on transcriptional activation reported here occurred in the absence of exogenous damage, it is possible that transcription-associated DNA breaks may contribute to observed DNA-PKcs activation. Irrespective of the means of activation, the findings herein demonstrate that DNA-PKcs interacts with known transcriptional modulators, binds to sites of transcriptional activation, and selectively engages a transcriptional network of strong cancer relevance.

The concept that DNA-PKcs suppresses UGT2B15 and 2B17 enzyme expression at least partially through NCoR and SMRT provides insight into how this PCA-relevant pathway is governed (Chouinard et al., 2006). Deregulation of androgen metabolism contributes to PCa progression (Chang et al., 2013) and may contribute to metastatic development (Mitsiades et al., 2012). Gene suppressive roles for DNA-PKcs have previously been reported (Hill et al., 2011; Jeyakumar et al., 2007; Yu et al., 2006), suggesting that DNA-PKcs-mediated transcriptional repression is not unique. Although AR is required for basal expression of both UGT2B15 and 2B17, stimulation with androgen results in gene downregulation (Bao et al., 2008), suggesting that resurgent AR signaling in CRPC may have a role in DNA-PKcs-mediated transcriptional repression of UGT enzyme expression. Factors influencing UGT expression in non-prostatic tissues include NRF and SP1 (Mackenzie et al., 2010), and influence on these factors may contribute to the impact of DNA-PKcs. Because UGT2B15 and 2B17 are being evaluated as pharmacologic targets for PCa management (Grosse et al., 2013), the identified link to DNA-PKcs may prove important in designing therapeutic regimens.

Identification of DNA-PKcs as a master regulator of pro-metastatic signaling complements previous studies linking the kinase to cancer-associated transcription factors (Brenner et al., 2011). The top scoring pathway for positively regulated DNA-PKcs genes is focal adhesion, hallmarked by factors that contribute to progression of multiple malignancies. Although the mechanisms regulating ITGB4, PREX1, ROCK2, and VAV3 expression are not well defined, previous reports identified binding sites for DNA-PKcs interacting transcription factors within regulatory regions. Moreover, promoter motif analysis of genes sensitive to DNA-PKcs depletion revealed enrichment for binding sites of DNA-PKcs interacting transcription factors (e.g., SP1, LEF1, and MYC). The AR binding sequence was not among the top motifs identified, likely influenced by the fact that androgen
Figure 6. DNA-PKcs Inhibitors Delay Formation of Metastases In Vivo

(A) Mice were injected with luciferin 31 days post-tail vein injection of PC3-ML cells and imaged using the IVIS imaging system with total luciferase signal reported (left) and representative images shown (right). Indicated mice were selected for crossover studies.

(B and C) Mice were injected with luciferin and imaged for 2 weeks after initiation of crossover studies with total luciferase signal reported (left), representative images shown (middle), and average doubling times pre- and post-crossover calculated.

(D) CASP-NPK-YFP tumors were measured twice weekly for 30 days after initiation of treatment (endpoint for survival was the predefined tumor volume of 1.5 cm³) with volumes calculated using the formula \( V = \text{width}^2 \times \text{length}/2 \).

(legend continued on next page)
response elements (AREs) are present at only \( \sim 40\% \) of known AR-binding sites, and AR primarily regulates transcription from enhancers (Yu et al., 2010). However, one of the top motifs identified was ELK1, an ETS domain factor required for expression of a major subset of AR target genes (Patki et al., 2013), supporting the finding that DNA-PKcs modulates AR-dependent transcription. Characterization of genome-wide DNA-PKcs occupancy combined with identification of the DNA-PKcs-associated proteome is a focus of current studies and will help to completely define partners of DNA-PKcs used to selectively modulate transcription.

A major consequence of DNA-PKcs-mediated transcriptional regulation is tumor metastasis, and the Rho/Rac pathway was identified as a critical effector of DNA-PKcs activity. Previous studies established a role for Rho/Rac signaling in metastases (Matsuoka and Yashiro, 2014). The finding that ROCK2 and DNA-PKcs inhibitors functioned cooperatively to suppress migration and invasion suggests that pathways in addition to Rho/Rac signaling may contribute to DNA-PKcs-induced metastasis (eg Wnt-\( \beta \)-catenin, TGF\( \beta \)), and it is intriguing to speculate that DNA-PKcs forms a central signaling point modulating metastatic networks. The importance of DNA-PKcs in metastatic formation was confirmed in multiple in vivo models, as inhibition of DNA-PKcs activity strongly delayed formation of metastases, and crossover studies suggest that DNA-PKcs functions early in establishment of metastatic lesions. Combined, these findings provide comprehensive analysis of cancer-associated factors regulated by DNA-PKcs and identify DNA-PKcs-mediated transcriptional regulation as a driver of metastasis.

Finally, findings herein provide robust clinical evidence of DNA-PKcs as promoting metastasis in human disease and as a candidate biomarker to predict poor outcome. Despite recent advances (Mitsiades et al., 2012), clinical biomarkers predicting progression or therapeutic response in PCa are lacking. Analyses of clinical samples demonstrated that high DNA-PKcs expression strongly correlates with decreased freedom from recurrence, freedom from metastases, and survival, implicating DNA-PKcs as a major driver of lethal cancer development. Strikingly, DNA-PKcs held similar prognostic value to Gleason score, underscoring its importance in disease progression. Additionally, a second independent analysis revealed that DNA-PKcs phosphorylation on residues associated with activation (Thr2609) and chromatin binding (Thr2609, Ser2612) is highly enriched in metastatic versus treatment-naive tissues, indicating that DNA-PKcs is highly active in metastatic PCa, independent of DNA damage markers. Although it was previously thought that DNA-PKcs activation occurs only through Ku-mediated binding to broken DNA, recent studies identified additional

---

**Figure 7. DNA-PKcs Inhibition Modulates Expression of Pro-metastatic Factors in Primary Human Disease**

(A) Schematic of explant assay, adapted from Schiewer et al., 2012.

(B) Representative images of explant tissues treated with control or 1 \( \mu \)M NU7441 and stained with hematoxylin & eosin.

(C) Explant tissues were harvested on day 6 for qPCR analysis with indicated transcripts set relative to GAPDH. Data are reported as mean ± SD. *p < 0.05.
Figure 8. DNA-PKcs Is Associated Clinically with Disease Recurrence and Metastases

(A–C) Tumor samples were profiled for DNA-PKcs mRNA, which was split into high versus low by the 80th percentile for Kaplan Meier analysis.

(D–G) GSEA analyses showed enrichment of the AR pathway (D), MAZ (E), and SP1 (F) targets, and the focal adhesion pathway (G) in genes correlated to DNA-PKcs.

(H) DNA-PKcs and histone H2AX phosphorylation were measured by mass spectrometry in organ confined, treatment-naive PCa and metastatic CRPC tissues.

(legend continued on next page)
mechanisms that contribute to DNA-PKcs activation, such as interaction with factors including AKT, EGFR, CK2, and multiple protein phosphatases (Douglas et al., 2001; Goodwin and Knudsen, 2014). Although future studies are required to determine which (if any) of these mechanisms contribute to DNA-PKcs activation in the context of transcription, the kinase activity of DNA-PKcs is targetable, and DNA-PKcs inhibitors are currently in clinical trials for advanced solid tumors, hematologic malignancies, and metastases (http://www.clinicaltrials.gov, NCT01336325). Because the development of metastases is nearly universally lethal in solid tumors, the clinical value in targeting DNA-PKcs for prevention of metastatic development in multiple malignancies should be evaluated.

In sum, the studies herein reveal paradigms for DNA-PKcs activity, unveil definitive transcriptional regulatory functions that promote the development of lethal tumor phenotypes, and nominate DNA-PKcs as a therapeutic target.

**EXPERIMENTAL PROCEDURES**

**Tail Vein Assays**

Mouse studies were performed with Thomas Jefferson University IACUC approval. PCs-ML or 22Rv1 cells expressing luciferase were pre-treated for 48 hr with 1 μM NU7441 or DMSO. After 48 hr, 1 x 10⁶ cells were seeded in hormone-proficient media for viability studies and 5 x 10⁵ cells in 100 μl PBS were injected into the tail veins of 6-week-old SCID mice. Cell number and viability were determined via trypan blue exclusion. Mice were treated every 24 hr 5 days/week with 25 mg/kg NU7441 or control through intraperitoneal (i.p.) injection. Tumor volume was monitored by i.p. injection of 150 μl RediJect D-Luciferin followed by IVIS imaging, with tumor volume quantified by Living Image Software. At day 31 of the PC3-ML study, three mice per cohort were selected for crossover studies. Mice not selected continued original treatment for an additional week. Crossover mice received new treatment for 2 weeks prior to sacrifice. Average doubling time pre- and post-crossover was determined using Tₙ = (q₂−q₁)/ln2/ln(q₂/q₁).

**Clinical Analyses**

**DNA-PKcs Expression**

Tumor samples were obtained from Mayo Clinic using a case-cohort study design to randomly sample 20% of patients for analysis, in addition to all in whom metastases developed, from a cohort of 1,010 high-risk men who underwent radical prostatectomy between 2000 and 2006, for a total cohort of 232 patients as described (Karnes et al., 2013). Studies were approved by the Mayo Clinic IRB and informed consent obtained from all subjects. DNA-PKcs expression was profiled using Affymetrix Human Exon 1.0 ST arrays. Expression data were normalized and summarized using the SCAN algorithm (Karnes et al., 2013). Expression was split into high versus low by the 80th percentile of DNA-PKcs expression. Gleason was split into high (8–10) versus intermediate/low (≤7). Kaplan Meier curves and p values were generated using the log-rank test. Expression of other genes was correlated with DNA-PKcs using Spearman’s correlation. Pre-ranked GSEA analyses were run using the Mayo Clinic laboratory for input. This work was supported by grants from PCF (to M.J.S.); PCF/Movember and Evans Foundation (to F.Y.F., S.A.T., and K.E.K.); PA CURE and NCI CA159945, CA176401 (to K.E.K.); DOD PCa Research program W81XWH-14-1-0148 (to J.M.D.); UCLA SOMI and NIH R25T CA098010 (to N.A.G.); NIH GM089778 (to J.A.W.); NCI CA168585 and ACS RSG-12-257-01-TBE (to T.G.G.); NCATS UCLA UL1TR000124 (to T.G.G. and O.N.W.); PCF (to O.N.W.); and NCI CA173481, CA183929 (to C.A.-S.). O.N.W. is an Investigator of the Howard Hughes Medical Institute and partially supported by a Stand Up to Cancer-PCF-Prostate Dream Team Translational Cancer Research Grant (co-PI), a grant made possible through the Movember Foundation. Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by AACR. K.E.K. receives research support from Celgene.

**DNA-PKcs Phosphorylation**

DNA-PKcs and H2AX phosphorylation were measured in organ-confined, treatment-naïve PCs and metastatic CRPC tissues (Drake et al., 2013). Studies were approved by the UCLA IRB and informed consent obtained from all subjects. Phosphopeptide enrichment was performed as previously described (Zimman et al., 2010) with minor modifications. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed using a Q-Exactive mass spectrometer. MS/MS fragmentation spectra were searched using Andromeda (Cox et al., 2011) against the Uniprot human reference proteome database with canonical and isoform sequences (downloaded January 2012 from http://www.uniprot.org) and a reversed decoy database with a false discovery rate <0.01. Search parameters included N-terminal acetylation and oxidized methionine as variable modifications and carbamidomethyl cysteine as a fixed modification. Variable modifications included phosphorylated serine, threonine, or tyrosine (phospho [STY]). In addition, group-specific parameters included maximum missed cleavages of 2. Search scores are reported in Table S2. Quantitation was performed using Skyline 2.6.0.6851 (Schilling et al., 2012). Prior to analysis, redundant spectral libraries were generated from Proteome Discoverer search results of the raw data files using the same Uniprot human reference proteome database. Retention time filtering was used so that only scans within 2 min of an MS/MS id were included. The precursor isotopic import filter was set to include only the first isotopeon (M0) at a Skyline resolution setting of 70,000. Reintegration of the peaks was performed with mProphet to improve peak picking, with a scoring model based on precursor mass error, identification, and co-elution count. Results were reported as areas under the curve (AUC) for each peptide. AUC values were compared across the treatment-naïve PCs and metastatic CRPC for DNA-PKcs and H2AX phosphopeptides. Relative fold changes for each phosphor-esidue as determined by the average of treatment-naïve and metastatic CRPC tissues were plotted. To calculate significance, two-tailed t tests or Mann-Whitney U tests were used for normally and non-normally distributed phosphopeptide data.

For details on other experiments, please refer to the Supplemental Experimental Procedures.

**ACCESSION NUMBERS**

The accession number for the microarray reported in this paper is GEO: GSE63480.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, six figures, and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.ccell.2015.06.004.

**ACKNOWLEDGMENTS**

The authors thank Dr. A. Fatatis and T.J. Stanek for reagents, and N. Erho (GenomeDx) and members of the K.E.K. laboratory for input. This work was supported by grants from PCF (to M.J.S.); PCF/Movember and Evans Foundation (to F.Y.F., S.A.T., and K.E.K.); PA CURE and NCI CA159945, CA176401 (to K.E.K.); DOD PCa Research program W81XWH-14-1-0148 (to J.M.D.); UCLA SOMI and NIH R25T CA098010 (to N.A.G.); NIH GM089778 (to J.A.W.); NCI CA168585 and ACS RSG-12-257-01-TBE (to T.G.G.); NCATS UCLA UL1TR000124 (to T.G.G. and O.N.W.); PCF (to O.N.W.); and NCI CA173481, CA183929 (to C.A.-S.). O.N.W. is an Investigator of the Howard Hughes Medical Institute and partially supported by a Stand Up to Cancer-PCF-Prostate Dream Team Translational Cancer Research Grant (co-PI), a grant made possible through the Movember Foundation. Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by AACR. K.E.K. receives research support from Celgene.

Received: December 1, 2014

Revised: April 2, 2015

Accepted: June 12, 2015

Published: July 13, 2015

(*) DNA-PKcs modulates cancer-associated transcriptional networks, inducing expression of AR targets and genes that regulate pro-metastatic Rho/Rac signaling pathways and suppressing expression of UGT enzymes known to affect DHT metabolism, identifying DNA-PKcs as a clinically actionable driver of metastatic CRPC.

Data are reported as mean ± SD. **p < 0.001, *p < 0.05. See also Figure S6 and Tables S1 and S2.
REFERENCES


Page 2812–2824.
DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis

Figure S1, related to Figure 1: DNA-PKcs binds AR and is recruited to sites of AR action. (A) 0.5 and 3 hour timepoints from main text Figure 1C. (B) C4-2 cells treated with 10 nM DHT were harvested for immunoblot analysis of total DNA-PKcs at the indicated timepoints with quantification performed using ImageJ software. (C,D) C4-2 cells (C) depleted of DNA-PKcs or (D) treated with 10 µM MDV3100 for 24 hours were harvested for ChIP-qPCR analysis and percent (input) occupancy of DNA-PKcs reported. Black bar represents control, colored bar represents treatment. (E) C4-2 were treated with 10 nM DHT and relative expression of indicated transcripts analyzed and normalized to GAPDH mRNA. Data are reported as mean +/- SD. *p<0.05 **p<0.01 compared to control.
Figure S2, related to figure 3: DNA-PKcs inhibition negatively regulates gene expression networks. (A,B) C4-2 cells depleted of DNA-PKcs or treated for 24 hours with 1 µM NU7441 were harvested for ChIP-qPCR analysis and percent (input) occupancy of NCoR (left) or SMRT (right) reported. Black bar represents Control, blue bar represents siDNA-PKcs, yellow bar represents NU7441. (C) C4-2 cells depleted of DNA-PKcs and treated with 10 nM DHT were harvested for qPCR analysis with the indicated transcripts set relative to GAPDH mRNA. (D) G-DHT levels 24 hours after 100 nM DHT treatment in 22Rv1 cells were determined by HPLC. (E) G-androsterone (G-AST) levels in C4-2 cells depleted of DNA-PKcs were determined by HPLC. (F) GSEA KEGG pathway analysis of genes identified to be upregulated by ≥1.5 fold compared to control after DNA-PKcs inhibitor treatment.
Figure S3, related to Figure 4: DNA-PKcs promotes pro-metastatic signaling. (A) Transcript expression of AR target genes from the microarray, 1.5 fold reduction for PSA and TMPRSS2 denoted. (B) GSEA KEGG pathway analysis of genes identified to be downregulated by ≥1.5 fold compared to control after DNA-PKcs inhibitor treatment. (C, D) Heat map of transcript change of pathways in cancer (C) or focal adhesion (D) pathway genes in the DNA-PKcs inhibitor treated groups. (E, F) C4-2 cells (F) depleted of DNA-PKcs using a non-pool siRNA or treated with 1µM NU7441 for 24 hours, (G) treated with 1µM NU7441 (non-pool) or 1µM NU7441 (pool) were subject to qPCR analysis with indicated transcripts set relative to GAPDH mRNA. (H) C4-2 cells depleted of SP1 or MAZ were harvested for ChIP-qPCR analysis and percent (input) occupancy of DNA-PKcs reported. Black bar represents control, colored bar represents treatment. (J) Quantification of GTP-bound Rho and Rac1 in main text Figure 4G. (K) C4-2 cells depleted of PREX1 or VAV3 were analyzed for activated (GTP-bound) Rho and Rac1 by column binding followed by immunoblot. Data are reported as mean ± SD. *p<0.05, **p<0.01 vs control.
Figure S4, related to Figure 5: UGT2B15 and UGT2B17 do not directly alter metastatic phenotypes. (A) LNCaP cells seeded into hormone deficient media and treated with 1µM NU7441 for the indicated timepoints were subject to BrdU FACS analysis and set relative to control. (B) Cells depleted of UGT2B15 or UGT2B17 were seeded into hormone deficient media and allowed to migrate (top) for 24 hours or invade through matrigel (bottom) for 72 hours towards hormone proficient media.
Figure S5, related to Figure 6: DNA-PKcsi inhibitors delay formation of metastases in vivo. (A) Schematic of tail vein injection experimental design (top). Overall cell number (bottom left) and percentage of trypan blue positive cells (bottom right) were determined by trypan blue exclusion at the indicated time points for PC3-ML cells pretreated with 1µM NU7441 for 48 hours. (B) Mice not selected for crossover studies were injected with luciferin 38 days post tail vein injection of PC3-ML cells and imaged using the IVIS imaging system with total luciferase signal reported. (C) Lungs harvested from mice in the crossover studies were stained with Ki67 and metastatic lesions scored (left) with representative images shown (right). (D) Mice were injected with luciferin 45 days post tail vein injection of 22Rv1 cells and imaged using the IVIS imaging system with total luciferase signal reported (left) and representative images shown (right). (E) Schematic of CASP-NPK-YFP experimental design. (F) Primary subcutaneous tumors were harvested and weighed at time of sacrifice. **p<0.01.
Figure S6, related to Figure 8: DNA-PKcs is associated clinically with disease recurrence and metastases. (A) Tumor samples were profiled for DNA-PKcs mRNA expression, split into high versus low by the 80th percentile of DNA-PKcs mRNA expression, and a Kaplan Meier curve generated. (B) GSEA analysis showed enrichment of the AR transcription factor pathway in genes correlated to DNA-PKcs in the tumor samples. (C) Tumor samples were profiled for mRNA expression of DNA-PKcs and AR (left), SP1 (middle), and MAZ (right) and correlation coefficients determined. (D) Tumor samples were profiled for UGT2B15 or UGT2B17 mRNA expression, which was split into high versus low by the 80th percentile of UGT2B15 (left) or UGT2B17 (right) mRNA expression for Kaplan Meier analysis.
Table S1, related to Figure 8. Provided as an excel file. List of pathways enriched in DNA-PKcs high tumors.

Table S2, related to Figure 8. Provided as an excel file. Mass spec peptide fragment data.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Cell Culture and Treatment

LNCaP and C4-2 cells were maintained in improved minimum essential media (IMEM) supplemented with 5% ΔFBS (heat-inactivated FBS). 22Rv1 and PC3-ML cells were maintained in Dulbecco’s modified Eagle’s media supplemented with 10% FBS. Cell lines used were not cultured longer than 6 months after receipt from the original source of American Type Culture Collection. All media were supplemented with 2 mmol/L of L-glutamine and 100 units/mL penicillin-streptomycin. For hormone deficient conditions, media used was phenol red-free media supplemented with 5 or 10% charcoal dextran-treated serum (CDT). DHT was obtained from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in ethanol. NU7441 and NU7026 were obtained from Selleckchem (Houston, TX, USA) and SLx-2119 was obtained from MedChem Express (Monmouth Junction, NJ, USA), and both were dissolved in DMSO. All experiments were seeded onto poly-L-lysine coated plates and allowed to adhere for 24 hours before initiation of treatments.

Chromatin Immunoprecipitation

Cells were seeded in hormone-proficient media and treated as specified. Cells were fixed with 1% formaldehyde at indicated timepoints and ChIP analyses conducted as previously described [Goodwin et al., 2013]. Genomic DNA was purified and quantitative PCR conducted for indicated loci using primers described. Negative control primers (Chr12 Intergenic) were designed to target the gene desert region chr12:60913317-60913384. Data were analyzed as percentage of input of total samples.

Co-immunoprecipitation

Cells seeded in hormone-proficient conditions were treated with 1µM NU7441 or 10nM DHT and harvested 6 hours post treatment. Cell pellets were lysed in NETN buffer with protease and phosphatase inhibitors added fresh, treated for 30 minutes on ice with 50ug/mL ethidium bromide or control, and clarified. 1000-2000ug of lysates were added to protein A (polycolonal, rabbit) or protein G (monoclonal, mouse) Dynabeads pre-incubated for 2 hours with 5ug of appropriate antibody and incubated overnight, with remaining lysate being diluted 1:1 with 2x SDS running buffer and retained as
Dynabeads were washed 3 times in NETN buffer, resuspended in 1:1 NETN: 2x SDS running buffer, boiled for 15 minutes, and analyzed by immunoblot analysis using antibodies described.

**Immunoblotting**

Cells were seeded in hormone-proficient or hormone-deficient conditions and treated as described. Cell lysates were generated and analyzed as previously described [Goodwin et al., 2013] using antibodies described.

**Gene Expression**

Cells were seeded in hormone-proficient media and treated as specified. RNA was isolated using TRIzol (Life Technologies #15596018) and quantitative PCR conducted as previously described [Goodwin et al., 2013] using primers described.

**RNA Interference**

Cells were seeded at a density of $1 \times 10^5$ in hormone-proficient conditions (complete media) for 24 hours. Cells were then transfected (6-8) hours in serum-free conditions with either control, PRKDC, ATM, Sp1, MAZ, PREX1, VAV3, UGT2B15, or UGT2B17 siRNA pools (Thermo Scientific, D-001810-10-20, L-005084-00-005, L-003201-00-0010, L-026959000-0010, L-012588-00-0010, L-010063-01-0010, L-010178-00-0010, L-020194-02-005, or L-020195-00-005, respectively) or control or PRKDC non-pool siRNA (Life Technologies, AM4611 or AM51331, respectively) according to the manufacturer's specifications. Cells were maintained in complete media for an additional 96 hours then seeded in hormone-proficient or hormone-deficient conditions and harvested at indicated timepoints.

**Microarray**

mRNA was harvested from cells depleted of DNA-PKcs or treated with 1µM NU7441 or control for 24 hours (minimum of 2 biological replicates per condition) and cDNA generated using the Ovation Pico WTA-system V2 RNA amplification system (NuGen Technologies, Inc.). cDNA was fragmented and chemically labeled with biotin using the FL-Ovation cDNA biotin module (NuGen Technologies, Inc.). cDNA in 200 uL hybridization cocktail was hybridized on the Affymetrix Human Gene 2.0 ST Array (Affymetrix #902112) in a GeneChip Hybridization Oven 645. Chips were scanned on an Affymetrix Gene Chip Scanner 3000 and data processed using GeneSpring V11.5 software with an Interactive
Plier16 summarization algorithm, quantile normalization, baseline transformation of median of all samples, and filtering to remove low expressing genes. A 1.5-fold differentially expressed gene list was generated. Gene lists were analyzed using Gene Set Enrichment Analysis (GSEA) [Mootha et al., 2003; Subramanian et al., 2005].

**Rac and Rho Activity**

Cells were seeded at a density of 5 x 10^5 in hormone-proficient media and treated as specified. Cells were lysed and assayed using Active Rho or Active Rac1 Detection Kits (Cell Signaling, #8820 or #8815, respectively) per manufacturer’s instructions. Briefly, 600ug of lysate was incubated with GST-Rhotekin-RBD fusion protein or GST-PAK1-PBD fusion protein to bind GTP-bound Rho or Rac1, respectively, which were immunoprecipitated with glutathione resin. Additional lysates were used as control inputs to determine total Rho or Rac1 levels. Input and immunoprecipitated samples were subject to immunoblot analysis using anti-Rho or anti-Rac antibodies provided in kits.

**DHT Measurement**

Performed as previously described [Chang et al., 2013], with minor deviations. Briefly, 1 x 10^6 C4-2 cells were transfected with siControl or siPRKDC. After 96 hours of transfection, 1ml serum free RPMI1640 was changed and treated with [^3H]-labeled (500,000 – 1,000,000 cpm, PerkinElmer) and non-radiolabeled DHT (100nM). Media was collected at 3, 6, 12 or 24 hours, with the results of 24 hours shown. The non-glucuronidated DHT was extracted by isoctane, evaporated, and analyzed using HPLC. To eliminate the remaining non-glucuronidated DHT contamination, the media was extracted three times. Post extraction, the water phase, which contained glucuronidated DHT, was treated with β-glucuronidase (1,000 units; Sigma-Aldrich) at 65°C for 4 hr followed by extraction, as described previously.

**Migration and Invasion**

2.5 x 10^4 cells depleted of DNA-PKcs or pre-treated with 1µM NU7441 or SLx-2119 for 24 hours were seeded into 0.5 mL serum-free media, added to the wells of Fluoroblok multiwell migration plates (Corning #351157) or Fluoroblok biocoat tumor invasion plates (Corning #354165) plates, and allowed to migrate or invade through a matrix towards 0.75 mL serum-containing media for 24 or 72 hours,
respectively. At the indicated timepoints, cell inserts were transferred to a 24 well plate containing 1 mL of 4μg/mL Calcein AM (Corning #354217) per well and incubated for 1 hour at 37° C. Fluorescent signal was determined using a Biotek Synergy HT plate reader and images obtained on a Leica DFC310 FX fluorescent microscope.

**Flow Cytometry**

5 x 10⁵ cells were seeded into serum-free media for 24 hours prior to treatment with 1μM NU7441. Cells were labeled with BrdUrd (1:1,000, GE Healthcare Life Sciences #RPN201) 1 hour prior to harvest, then fixed, stained, and processed as previously described [Goodwin et al., 2013].

**Immunohistochemistry**

Tissues for immunohistochemical analysis were fixed and formalin and embedded into paraffin blocks. All immunohistochemical staining was performed by the Thomas Jefferson University Histology/Immunohistochemistry core facility, with Ki67 scored by pathologist. Briefly, tissue sections were deparaffinized in xylene and rehydrated through an ethanol gradient. For histological analysis, sections were stained with hematoxylin and eosin (H&E) using standard techniques. For analysis of Ki67, sections were initially boiled in Antigen Retrieval Solution (Dako North America, Inc.) using a microwave (5 minutes at 100% power followed by 20 minutes at 30% power). Sections were then cooled to room temperature, and endogenous peroxidase activity was quenched by treatment in 0.3% H₂O₂ in methanol (Dako North America, Inc.). Samples were blocked for 30 minutes in 5% goat serum in PBS. Primary Ki67 (MIB-1, Dako North America, Inc.) antibody was diluted 1:250 in blocking buffer and incubated for 1 hour at room temperature. Following washing with PBS, biotinylated secondary antibody and streptavidin-peroxidase conjugate were applied according to kit instructions (Vector Laboratories) for 1-2 minutes and quenched with H₂O. Slides were counterstained with hematoxylin, dehydrated through graded ethanols and xylene, and mounted using permount (Surgipath Medical Industries, Inc.).

**CASP-NPK-YFP In Vivo Metastasis Model**

For in vivo studies, 3x10⁶ CASP-NPK-YFP cells [Aytes et al., 2013] were mixed with Matrigel (1:1 v/v) and injected into the right flank of immunodeficient NCr nude mice (Taconic). Five days after engraftement, mice were randomized to be enrolled into vehicle or NU7441 treatment (25 mg/kg). Briefly,
vehicle or NU-7441 was administered intraperitoneally five days a week (Monday to Friday); tumors were measured using calipers twice a week and volumes calculated using the formula \( \text{Volume} = (\text{width})^2 \times \text{length}/2 \). Tumor growth and body weights were monitored for 30 days after initiation of treatment. At the time of sacrifice, subcutaneous tumors were harvested and weighted, and metastases were documented in the lungs and livers by visualizing fluorescence using an Olympus SZX16 microscope equipped with epi-fluorescence capabilities. The total number of metastatic nodules for the lungs and livers of each mouse was assessed and the \( p \)-value of the difference calculated using the Mann-Whitney U test. RNA from was extracted from the subcutaneous primary tumors using the MagMAX Total RNA Isolation Kit (Life Technologies, #AM1830) per manufacturer’s instructions.

**Human Prostate Tumor Explants**

Human prostate ex vivo explant cultures were conducted as previously described [Centenera et al., 2013]. Briefly, fresh primary tumor tissue was obtained from a clinical pathologist immediately following radical prostatectomy at Thomas Jefferson University Hospital in accordance with Institutional Review Board standards and in compliance with federal regulations governing research on deidentified specimens and/or clinical data (45 CFR 46.102(f)). The deidentified specimen was processed under laminar flow hood using sterile technique and transported in culture media (IMEM, 5% FBS, 0.01 mg/mL insulin (Invitrogen #12585-014), 30 umol/L hydrocortisone (Sigma #H-0888), and penicillin/streptomycin) on ice. Tissue was subdivided into approximately \( 1\text{mm}^3 \) pieces and placed in a 24-well plate on presoaked dental sponges (Novartis #96002) (2-3 pieces per sponge) placed into 0.5 mL culture media in presence or absence of drug (control or 1µM NU7441). Plates were placed in an incubator at 37°C and 5% \( \text{CO}_2 \). Media were replaced every 48 hours with appropriate treatment, and explants were harvested on day 6. Tissue was either formalin fixed for immunohistochemical analysis or placed in 1 mL RNAlater (Ambion #AM7020) (kept at 4°C for 24 hours, then stored at -80°C until processing) for RNA analysis. RNA extraction was performed using Trizol (Life Technologies #15596018) per manufacturer’s instructions.
Antibodies

Antibodies used for ChIP experiments were as follows: AR (N-20, directed against amino acids 1-20 by Bethyl Laboratories), DNA-PKcs (Thermo Scientific, #423-PABX), p300 (Active Motif, #61401), RNA Polymerase II (Santa Cruz Biotechnology, #SC-899X), NCoR (Abcam, #24552), and SMRT (Abcam, #24551). Antibodies used for immunoblot were as follows: DNA-PKcs (phospho S2056) (Abcam, #18192), DNA-PKcs (Thermo Scientific, #423-PABX), Lamin B (Santa Cruz, #6217), AR (N-20, directed against amino acids 1-20 by Bethyl Laboratories), Vinculin (Sigma-Aldrich, #V9264-200UL), UGT2B15 (Abcam, #83468), UGT2B17 (Abcam, #92610), PREX1 (EMD Millipore, #MABC178), ROCK2 (Abcam, #71598), ITGB4 (Abcam, #29042), VAV3 (EMD Millipore, #07-464), Ku70 (Thermo Scientific, #329-P0), ATM (Cell Signaling, #2873), Sp1 (Abcam, #77441), and MAZ (Abcam, #85725).

Statistical Analysis

All pooled data are represented as mean +/- standard deviation. P-values were calculated using Student’s t test.

Primers

<table>
<thead>
<tr>
<th>ChIP Primers</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLK3/PSA Enhancer</td>
<td>TGGGACAAACTTGCAAACCTG</td>
<td>CCAGAGTAGGTCTGTCTTTTCAATCCA</td>
</tr>
<tr>
<td>TMPRSS2 Enhancer V</td>
<td>TGGTCCTGGATGATAAAAAAAGTTT</td>
<td>GACATACGCCACACAACAGA</td>
</tr>
<tr>
<td>Chr12 Intergenic</td>
<td>GGGATGATGTGTGGGTATTTACC</td>
<td>CAATATCCAGCGAAAAGGAAGCT</td>
</tr>
<tr>
<td>UGT2B15 Promoter</td>
<td>TCATGACCCCTCTGAACAGC</td>
<td>CTCTGGAAGCTGTGGAAAGGT</td>
</tr>
<tr>
<td>UGT2B17 Promoter</td>
<td>TGAGCTGCATCAGCAGAAAGA</td>
<td>AAGCACTGCATAAGGACCAGGA</td>
</tr>
<tr>
<td>PREX1 Promoter [Wong et al., 2011]</td>
<td>GCCAAGGCGACCGCGCCGCCGCCCTCC</td>
<td>TCAGCAGCGGCGCCCGGCTCCC</td>
</tr>
<tr>
<td>ROCK2 Promoter</td>
<td>AATGGTGCGCGCTGCTGATGAG</td>
<td>TCTGCTACTGTCGCGCTATG</td>
</tr>
<tr>
<td>ITGB4 Promoter [Drake et al., 2010]</td>
<td>CTGCAGCCCACATCTCCTA</td>
<td>CCCGTCCTGGACCTACCT</td>
</tr>
<tr>
<td>PLA1A Promoter [Brenner et al., 2011]</td>
<td>TGGCCACCCAGAGATGCAGGA</td>
<td>ACACACTGTCCTCTTTTGGAGCCA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>mRNA Primers</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLK3/PSA</td>
<td>TGTGTGCTGGACGCTGGA</td>
<td>CACTGCCCATGACGTGAT</td>
</tr>
<tr>
<td>TMPRSS2</td>
<td>GGACAGTGTCACCTCAAAGAC</td>
<td>TCCCAGGAGGAGGCTCCC</td>
</tr>
<tr>
<td>GAPDH</td>
<td>AACAGCCTCAAGATCATCAG</td>
<td>CATGAGTCTCCACGATAC</td>
</tr>
<tr>
<td>Gene</td>
<td>Forward Primer</td>
<td>Reverse Primer</td>
</tr>
<tr>
<td>---------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>UGT2B15</td>
<td>GTGTTGGGAATATTATGACTACAGTAAC</td>
<td>GGGTATGTTAAATAGTTCAGCCAGT</td>
</tr>
<tr>
<td>UGT2B17</td>
<td>TTTTGTGCAGGAAAAAGGAAA</td>
<td>AAGCCTGAAGTGGAATGACCAAG</td>
</tr>
<tr>
<td>PREX1 [Wong et al., 2011]</td>
<td>CTTTCTCTCCTTCGACAAC</td>
<td>GTGGAGAATGTGGAAGATGG</td>
</tr>
<tr>
<td>ROCK2</td>
<td>TCCCCCATCAACGGAGAGCT</td>
<td>TGCTTTGTGACGAACCAACTGCA</td>
</tr>
<tr>
<td>ITGB4</td>
<td>AGGGTCAGTTCTGCGAGTATG</td>
<td>GTCCATTACAGATGCCCCCAT</td>
</tr>
<tr>
<td>VAV3</td>
<td>AGCTAAGGTTGCTAACAAACA</td>
<td>TCCATTGGTCGTTTCTCTGG</td>
</tr>
<tr>
<td>PLA1A</td>
<td>CTGAGATTTCAGCTCAGCGA</td>
<td>CACCCAGCACCAGGAGTTTAT</td>
</tr>
<tr>
<td>Gapdh</td>
<td>AATGAGAGAGGCCCAGCTACT</td>
<td>CCAATACGGCCAAATTCCGTTT</td>
</tr>
<tr>
<td>Prex1</td>
<td>TACGACGACGGCACTTACAAA</td>
<td>CAGTAGAGTCTCAGGCCTTGG</td>
</tr>
<tr>
<td>Rock2</td>
<td>GTCTGCTGGATGCTTTGTTATCC</td>
<td>TTGGCCACTTTTCAGGTACA</td>
</tr>
<tr>
<td>Itgb4</td>
<td>GCGTTTCTGATGACACTGAGC</td>
<td>CACGGGAATCTTGGGAGGAAAG</td>
</tr>
<tr>
<td>Vav3</td>
<td>AGTCGGAAGCCAGTGCTCA</td>
<td>TCCACGCGGGTTTTCATCTATT</td>
</tr>
</tbody>
</table>